Experience

Davis Polk advised the underwriters in connection with a public offering of 6,666,667 shares of common stock of IDEAYA Biosciences, Inc. at $15.00 per share, for total gross proceeds of …

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $192.5 million offering of common stock of Constellation…

Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 1,955,000 shares of common stock for an aggregate price to the public of approximately $89.4 million,…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…

Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering of 12,105,263 shares of common stock of Generation Bio Co., which…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics, Inc. of shares of its common stock for up to a maximum offering…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5,980,000 shares of common stock of ChemoCentryx, Inc. (which…

Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceuticals plc, of $850 million aggregate…

Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend Biotech Corporation of 21,188,750 American Depositary Shares, each…

Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Humanigen Inc. of $72 million of common stock. Humanigen Inc. is a clinical…